Why Are Zogenix’s Shares Gaining Today?
The FDA has granted Priority Review to Zogenix Inc's (NASDAQ:
Recap: Zogenix Q3 Earnings
Zogenix (NASDAQ:ZGNX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
Zogenix Earnings Preview
Zogenix (NASDAQ:ZGNX) is set to give its latest quarterly earnings report on Thursday, 2021-11-04. Here's what investors need to know before the announcement.
Analysts estimate that Zogenix will likely report an Earnings Per Share (EPS) of $-0.97
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Zogenix Sponsored Study Titled ‘A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder’ Posted To ClinicalTrials.gov, Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05064878
Zogenix’s Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy
Zogenix Inc (NASDAQ:ZGNX) has announced interim data from an ongoing 12-month Phase 3 open-label extension (OLE) study of Fintepla (fenfluramine) in…
Zogenix Reports Submission Of Supplemental New Drug Application For FINTEPLA For Treatment Of Seizures Associated With Lennox-Gastaut Syndrome
Supplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Company's Phase 3 trial, Study 1601, in which the primary endpoint was met with high
